









Markets
/
Stocks
/
nasdaq-ntrbw
/

Nutriband Inc

NTRBW

View Detailed Chart

2.680

+0.580+27.62%

Market hours （ET）Quotes delayed by 15 min

--Market Cap

--P/E TTM



Nutriband Inc

2.680

+0.580+27.62%

Company

Intraday

30m

Today

+27.62%

5 Days

+Infinity%

1 Month

+41.05%

6 Months

+44.86%

Year to Date

+91.43%

1 Year

+123.33%

View Detailed Chart

Agency Rating

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Buy

Sell(1)

Neutral(2)

Buy(10)

Indicators

Sell(1)

Neutral(2)

Buy(4)

Indicators

Value

Direction

MACD(12,26,9)

0.368

Neutral

RSI(14)

53.806

Neutral

STOCH(KDJ)(9,3,3)

66.027

Buy

ATR(14)

1.373

Low Volatility

CCI(14)

109.942

Buy

Williams %R

31.596

Buy

TRIX(12,20)

0.457

Sell

StochRSI(14)

72.847

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

1.546

Buy

MA10

0.943

Buy

MA20

0.888

Buy

MA50

0.952

Buy

MA100

1.505

Buy

MA200

1.330

Buy

News

More news coming soon, stay tuned...

Company

Nutriband Inc. is engaged in the development of a portfolio of transdermal pharmaceutical products. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. Its lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. Its development pipeline also includes AVERSA Buprenorphine and AVERSA Methylphenidate. It is developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.

Company codeNTRBW

CompanyNutriband Inc

CEOMr. Gareth Sheridan

Websitehttps://nutriband.com/